If inadequate control of the complement system caused by genetic predisposition is involved in SLE nephritis, it could become an additional indication for use of the emerging complement inhibitors such as eculizumab, which is a monoclonal antibody inhibiting cleavage and activation of C5. The gene discussed is C5; the disease is lupus nephritis.